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Coronary angiography after myocardial infarction is one of
the most well-studied procedures in contemporary medical
care (1), yet substantial geographic variability persists in the
use of this procedure both within the U.S. (2,3) and
between the U.S. and Canada (4–6). In this issue of the
Journal, Batchelor et al. (7) described the effect of this
variability on the detection of severe coronary artery disease
(CAD), and they attempted to assess its implications for
patients’ outcomes (7).
Using data from the Global Use of Strategies to Open
Occluded Arteries in Acute Coronary Syndromes
(GUSTO-1) trial, Batchelor et al. (7) compared the fre-
quency with which patients with severe (left-main or three-
vessel) CAD were detected in the U.S. and Canada. On the
basis of earlier randomized clinical trials, these patients were
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likely to experience reduced mortality over five years if they
underwent coronary artery bypass graft (CABG) surgery
rather than continuing with medical therapy alone (8). As
previously reported from the GUSTO-1 trial (5), U.S.
patients underwent coronary angiography much more often
than clinically comparable Canadian patients (71% vs. 27%).
Batchelor et al. (7) extended this finding by evaluating the
results of coronary angiography. In the U.S., approximately
two-thirds of patients with severe CAD were detected by
angiography, whereas in Canada only about one-fifth of
such patients were identified. Although no actual outcomes
were presented for these patients, the investigators esti-
mated that five more patients would be expected to survive
five years for every 1,000 patients treated with the more
frequent use of angiography and CABG surgery in the U.S.
relative to the more conservative Canadian approach.
This gain, however, came at the cost of performing many
more angiograms in the U.S. in patients without severe
CAD (59% of all patients in the U.S. vs. 22% of all patients
in Canada). Some of these patients experienced recurrent
ischemia or reinfarction and probably benefited from per-
cutaneous transluminal coronary angioplasty (PTCA) for
one- or two-vessel disease, but most of them seemed to
have had uncomplicated myocardial infarctions (9).
Presumably, U.S. physicians were tempted to “take a look”
at such patients’ coronary anatomy with the hope of detect-
ing unrecognized severe disease or performing elective
PTCA.
When interpreting analyses of clinical practices from
GUSTO-1 or other randomized clinical trials, readers
should carefully consider whether the study’s patients are
representative of the broader population of interest. In the
case of GUSTO-1, all patients met strict eligibility criteria
for the administration of thrombolytic therapy (presentation
within 6 h of the onset of symptoms, ST elevation on the
initial electrocardiogram and no major contraindications),
and almost all patients actually received this treatment (9).
Participating hospitals were much more likely to offer
coronary angiography and revascularization procedures on-
site than were U.S. and Canadian hospitals in general (5,6).
Moreover, patients who enrolled in GUSTO-1 were
younger and had fewer coexisting illnesses than patients
who were not enrolled (10). GUSTO-1 patients in both the
U.S. and Canada were more likely to undergo coronary
procedures than patients with myocardial infarction (MI) in
either country usually do.
Nonetheless, the findings of Batchelor et al. (7) are
probably generalizable to more typical patients with MI in
these two countries. The substantially greater use of coro-
nary angiography and revascularization procedures in
post-MI patients in the U.S. compared with Canada has
also been described in the Survival and Ventricular Enlarge-
ment trial with different enrollment criteria (4) as well as in
a population-based study based on administrative data (6).
Therefore, the greater diagnostic yield for detecting severe
CAD in the U.S. relative to Canada would also probably be
present in less narrowly defined cohorts from these two
countries.
What lessons can physicians and policymakers draw from
this study? Before angiography, neither U.S. nor Canadian
physicians identified patients with an increased risk of severe
CAD at a frequency greater than chance. This finding
highlights the need for better statistical tools to predict
severe CAD. Such tools must incorporate readily available
clinical information, have reasonable accuracy and be well
disseminated if they are to be useful to practicing physicians.
Although such tools were not a primary focus of their
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analysis, Batchelor et al. (7) generated one such tool from
GUSTO-1 data, using six simple variables to achieve
moderate accuracy in predicting severe CAD. Further re-
finement of such tools could help physicians become more
selective in their use of coronary angiography after MI,
thereby recommending it more often to patients with a high
probability of severe disease and less often to patients with
a low likelihood.
A different approach to the selection of patients for early
coronary angiography was tested in the Thrombolysis in
Myocardial Infarction (TIMI) II trial (11), in which 3,262
patients with acute MI were randomized to either an
invasive or a conservative strategy. In the former, routine
coronary angiography was carried out 18 to 48 h after
admission, and in the latter, predischarge stress testing was
performed and angiography carried out if spontaneous or
stress-provoked ischemia was detected. In both groups,
revascularization was carried out if the coronary anatomy
was appropriate. In the invasive strategy, 63% of the patients
underwent early revascularization, and in the conservative
arm, 33% had angiography (a percentage similar to the
Canadian patients in GUSTO-I) and only 20%, less than
one-third of those in the invasive arm, underwent revascu-
larization. Both early (six week) and late (three year)
follow-up showed essentially identical outcomes (12). Thus,
by limiting early postinfarction angiography to patients with
ischemia, the need for coronary angiography could be
greatly reduced without adversely affecting important out-
come end points (death, recurrent infarction as well as
ejection fraction at rest or during exercise). The value of this
approach was confirmed in the Should We Intervene
Following Thrombolysis? trial (13).
For Canadians, Batchelor et al. (7) have added to previ-
ous research that suggested that the restricted availability of
coronary angiography and revascularization procedures may
result in suboptimal relief of cardiac symptoms (4,5) and
possibly some increased risk of avoidable mortality, partic-
ularly for elderly patients (5,14). In the Canadian system of
global budgets for medical care, decisions to restrict coro-
nary procedures are fairly explicit. As long as citizens and
legislators are well aware of these restrictions and their
consequences, lower procedure rates and longer waits may
be acceptable to most Canadians. In the Canadian political
system, competing budgetary priorities within and beyond
health care have thus far been judged more compelling than
the need to increase the availability of coronary procedures
to U.S. levels. Nonetheless, Batchelor et al. (7) presented
evidence that low rates of coronary angiography for Cana-
dian patients over age 75 may fail to identify many patients
with severe CAD who would benefit from CABG surgery.
The ethical and clinical foundation for such rationing must
continue to be reevaluated as new data on the outcomes of
older patients become available.
In the U.S., a very different health-care system has
evolved. The Medicare program provides nearly universal
access to primary and specialty care for persons aged 65 and
older, but lack of insurance and low income can be major
barriers to coronary procedures for younger persons (15,16).
Moreover, a tradition of unrestricted fee-for-service care
and minimal regulation of cardiac services has resulted in
the wide dissemination of facilities for performing coronary
angiography and revascularization procedures. As a result,
well-insured patients with CAD can expect to receive
coronary angiography and revascularization procedures with
little or no delay, as demonstrated by the high U.S. rate of
angiography in GUSTO-1. Few U.S. patients or physicians
would seek to emulate the more restrictive approach to
coronary procedures found in Canada, but many would
welcome the more equitable access that the Canadian
system provides to low-income residents.
Rather than responding to U.S.–Canadian com-
parisons, U.S. physicians and policymakers are more likely
to react to strong evidence of geographic variations within
the U.S. Substantial differences in rates of coronary proce-
dures among U.S. regions—without clear effects on out-
comes—generate ample uncertainty about the appropriate
use of these resources (2,3). Past studies have demonstrated
that the on-site availability of coronary procedures is a major
factor determining whether patients receive them in the
U.S. (17–19). Paradoxically, this factor favors the selection
of younger and lower-risk patients for angiography—a
group that may derive limited benefit from this procedure
(20). Although economic incentives contribute to this pat-
tern of care, physicians who perform coronary procedures or
practice in hospitals that offer them actually perceive coro-
nary angiography as more beneficial than do other physi-
cians, particularly for patients with uncomplicated condi-
tions (21). Thus, altering physicians’ decision making about
this procedure will not be a simple task.
Future research can build on the work of Batchelor et al.
(7) by assessing how often severe CAD is detected and
appropriately managed in U.S. regions with widely varying
rates of coronary angiography. As the understanding of
CAD and its treatment evolves, studies of clinical practice
can illuminate how physicians balance the many clinical and
economic influences on their decision making—and the
subsequent effect of their decisions on patients’ outcomes.
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